About

Prof. Alan Palestine, MD

Alan Palestine, MD is a Professor of Ophthalmology and Rheumatology at the
University of Colorado Anschutz School of Medicine and is the Chief, Uveitis and Ocular
Immunology Section. He also serves as the Director of the Center for Ocular
Inflammation at the University of Colorado Department of Ophthalmology and Vice
Chair for Clinical Research.
Prof. Palestine specializes in ocular immunology and has over 40 years of experience in
treating non-infectious uveitis. He is an expert in the evaluation and management of
patients with uveitis and other related immune-mediated disorders.
He has published over 300 articles, 12 book chapters, and co-authored two books
including the 1 st edition of Uveitis: Fundamentals and Clinical Practice, which served as
a comprehensive, foundational text for understanding and treating uveitis.
He has served as an investigator in multiple clinical trials in uveitis and uveitic macular
edema including POINT, MERIT, HURON, Peachtree, Azalea, served as an investigator
for the Standardization of Uveitis Nomenclature (SUN) study and executive committee
member for the SUN working group, and served as Medical Officer and DSMC
Chairman for the Multicenter Uveitis Steroid Treatment (MUST) trial. Dr. Palestine is a
fellow of the American Academy of Ophthalmology (AAO), a member of the leadership
team of the American Uveitis Society (AUS), and active member of the Retina Society
and Macula Society.
Dr. Palestine earned his medical degree from the University of Rochester School of
Medicine. He completed his residency in Ophthalmology at the College of Medicine,
Mayo Clinic Rochester, and a fellowship in Ocular Immunology at the National Eye
Institute, National Institute of Health (NIH). Prior to joining the faculty at the University of
Colorado in 2012, where he has won the Academic Teaching Award in the Department
of Ophthalmology in 2015, 2017, and 2023, he had academic appointments at the
Wilmer Eye Institute and Johns Hopkins and Georgetown University.

Prof. Mina B. Pantcheva, MD

Dr. Mina Pantcheva is an Associate Professor of Ophthalmology in the Department of
Ophthalmology at the University of Colorado Anschutz School of Medicine. She is a
board-certified ophthalmologist, glaucoma specialist and leads the uveitic glaucoma
clinic at the Ocular Inflammation Multidisciplinary Clinic, Sue Anschutz-Rodgers Eye
Center.
Dr. Pantcheva earned her medical degree from the University of Sofia, Bulgaria. She
completed an internship in Internal Medicine at the Roger Williams Medical Center,
Boston University and a residency in Ophthalmology at the University of Pittsburg
Medical School, Eye & Ear Institute. Dr. Pantcheva also completed Glaucoma research
fellowship at Massachusetts Eye and Ear Infirmary, Harvard Medical School and
Glaucoma clinical fellowship at University of Pittsburg Medical School, Eye and Ear
Institute.
In 2023, she joined Eyegenex, a biotechnology company developing first-in-class
neuroprotective therapies for glaucoma and related optic neuropathies and currently
serves in the role of Chief Medical Advisor.
Dr. Pantcheva has served as a principal investigator or co-investigator on multiple
clinical trials in the areas of glaucoma and ocular hypertension. She is a clinician-
scientist whose research interests focus on clinical and surgical management of
glaucoma and uveitis, outcomes of innovative ophthalmic procedures and devices, and
translational research on trabecular meshwork disease mechanisms.
Dr. Pantcheva is an active member of the American Academy of Ophthalmology (AAO),
Association for Research in Vision and Ophthalmology (ARVO), the American
Glaucoma Society (AGS), Colorado Society of Eye Physicians and Surgeons (CSEPS),
and the Uveitic Glaucoma Interest Group (UGIG).

Ashley Hartmann Kline, Senior Commercial Advisor

Ashley Kline brings over 15 years of extensive experience in commercial leadership
within the biotech industry, with a strong focus on the commercialization of specialty
pharmaceuticals. She has dedicated a significant portion of her career to successfully
bringing innovative medicines to market, particularly in the field of ophthalmology.
Most recently, Ms. Kline was the US General Manager and Global Head of the Biotech
Business Unit at Italian pharma and biotech company Dompé. During that time she
brought Oxervate(TM) (cenegermin-bkbj) to market, a first-in-class recombinant
human nerve growth factor eye drop approved by the FDA for the rare eye disease
neurotrophic keratitis.
Kline has also worked in a variety of leadership and strategic roles in other sectors of
ophthalmology, including in uveitis and macular degeneration at companies including
Santen, Adverum Biotechnologies, and Genentech.
Ms. Kline earned her MBA from the Kellogg School of Management at Northwestern
University and her BA with distinction from the University of North Carolina at Chapel
Hill. She lives in the San Francisco Bay Area.

Emilee Fulcher, B.Sc - VP Clinical Affairs

Ms. Fulcher brings 20 years of experience in the pharmaceutical industry, with a specialized background in executing ophthalmology clinical trials. Ms. Fulcher has deep expertise in ophthalmic drug development, having successfully led clinical trials across multiple indications including anterior uveitis, dry eye disease, post-surgical inflammation, and age-related macular degeneration. Notably, Ms. Fulcher served a pivotal role in Tarsier Pharma’s TRS01 clinical program over the last 5 years, having managed all three trials completed to date.

Prior to officially joining Tarsier Pharma, Ms. Fulcher was one of the first employees of Lexitas, an ophthalmic-focused CRO, and during her 11-year tenure led numerous project teams and managed trials across all phases, including the trials that led to the approval of Xiidra^® and Inveltys^®. Prior to that, she served in several positions at Inspire Pharmaceuticals and UCB Biosciences, as a research scientist in preclinical drug development and in clinical operations. Ms. Fulcher holds a B.Sc. in Biology with a minor in Chemistry from the University of North Carolina at Chapel Hill.

TRS4Vision (TRS01 Eye Drops)

A Phase 3 clinical trial of a steroid-free eye drop (TRS01) in the treatment of subjects with active non-infectious anterior uveitis including subjects with uveitic glaucoma. Throughout the duration of this randomized, double-masked study, the safety and efficacy of TRS01 eye drops will be evaluated and compared to standard of care steroid eye drops. Participation is limited to subjects 70 years of age or younger (including children of all ages) who have active non-infectious anterior uveitis and are currently without treatment or on a stable dose of their current treatment. Subjects will be followed for 6 weeks over the course of 6 office visits.

Would you like to participate? You are welcome to answer TRS4VISION ELIGIBILITY QUETIONNAIRE or submit any inquiry to [email protected]

To learn more about the trial and to find out which clinical sites are on board, in the US and in Europe, please visit: Clinicaltrials.gov or visit the US Sites map.

Natan Haykin, M.Sc – Head of Chemistry (CMC)

Mr. Haykin brings expertise in peptide drug development with a proven track record in the chemical development of peptide-based APIs, from small R&D scales up to large-scale commercial manufacturing.

Prior to joining Tarsier Pharma, Mr. Haykin served in several positions at Novetide (partially owned by Teva Pharmaceuticals), a leading worldwide peptide manufacturer for the pharmaceutical industry. He was leading R&D teams and projects towards successful development of multi-kg scale GMP production of different peptide-based pharmaceutical products.

Mr. Haykin holds an M.Sc. in Biotechnology engineering from the Technion, the Israeli Institute of Technology.

Prof. Meghan Berkenstock, MD

Dr. Meghan Berkenstock is an Associate Professor of Ophthalmology at the Johns Hopkins Wilmer Eye Institute and Medical Director of the Johns Hopkins Wilmer Eye Institute at Water’s Edge. She specializes in ocular inflammatory and infectious diseases, cataract surgery, and comprehensive ophthalmology.

Dr. Berkenstock earned her medical degree from Drexel University College of Medicine. She completed her residency in Ophthalmology at the Hahnemann University Hospital, and a fellowship in Uveitis & External Disease at the UCLA Jules Stein Eye Institute.

In 2016, Dr. Berkenstock joined the faculty of the Wilmer Eye Institute, and her research focuses on risk reduction and quality assurance initiatives in the care of patients with uveitis. She serves as Johns Hopkins Medicine’s ocular toxicity specialist and is actively involved in research including immunotherapy-related ocular adverse events (IRAEs), serving as a member and the only ophthalmologist on the National Comprehensive Cancer Network Panel on developing guidelines to treat IRAEs. Her research interests also include juvenile idiopathic arthritis-related uveitis and prevention of glaucoma complications in these children. Dr. Berkenstock has published extensively on the topics of uveitis epidemiology, ocular toxicity, and uveitis-associated ocular hypertension and glaucoma.

She has served as an investigator in multiple clinical trials in uveitis and uveitic macular edema including ADVISE, POINT, and MERIT. Dr. Berkenstock is a board-certified ophthalmologist, uveitis specialist and an active member of the American Academy of Ophthalmology (AAO), Association for Research in Vision and Ophthalmology (ARVO), American Uveitis Society (AUS), and the International Uveitis Study Group (IUSG).

Jennifer Thorne, M.D., Ph.D.

Jennifer Thorne, M.D., Ph.D., is the Cross Family Professor of Ophthalmology at the Wilmer Eye Institute, where she is also chief of the Division of Ocular Immunology and Uveitis. Prof. Thorne holds a joint appointment as professor of epidemiology at the Johns Hopkins Bloomberg School of Public Health.

An internationally recognized and board-certified ophthalmologist, Prof. Thorne is an expert in the evaluation and management of patients with uveitis and other related immune-mediated disorders. She has published over 200 articles and book chapters on uveitis and ocular immunology, won approximately 30 scientific and clinical awards, and has participated in numerous uveitis clinical trials.

Prof. Thorne’s research interests include white dot syndromes including birdshot chorioretinitis, multifocal choroiditis and punctate inner choroiditis. She also studies juvenile idiopathic arthritis-related uveitis and treatment outcomes of immunosuppressive drug therapy.

Dr. Thorne is active in American and international Ophthalmology and uveitis-related forums, for example, she was President of the American Uveitis Society and remains part of its leadership team, was a member of the Executive and Steering Committees of the Standardization of Uveitis Nomenclature (SUN) Working Group and played advisory and editorial roles in the American Academy of Ophthalmology, Ocular Immunology and Inflammation journal, and more. She has also served as an advisor and consultant for ophthalmic pharma companies, such as Allergan, AbbVie, Gilead, and more.

Prof. Thorne received her M.D. degree from the University of Virginia and completed her ophthalmology residency at the University of Pennsylvania’s Scheie Eye Institute. She completed her uveitis fellowship at Wilmer and completed her Ph.D. in epidemiology at the Johns Hopkins Bloomberg School of Public Health.

Arie Ganot, CPA – CFO

Arie Ganot is an experienced professional in senior financial and executive roles, in private and public companies. Arie has strong capabilities in M&A, IPO, SEC accounting, budgeting, and equity raising. He has led the Mind CTI (Nasdaq: MNDO) successful IPO, a leading provider of billing and customer care solutions, and S.AL Technical Equipment’s IPO at TASE (Tel Aviv Stock Exchange), before its acquisition for 280 million NIS. Formerly, Arie has also been the CFO of Extricom, and a Senior Auditor in PWC. He has founded NatiG CPA, a CFO Services company, in which he serves as external CFO at selected companies. Arie Joined Tarsier’s team as CFO since its establishment in 2016. Arie holds a BA in Economics and Accounting from Tel Aviv University and is a Certified Public Accountant in Israel.

Jonathan Burgin, MBA, CPA – CFO

Jonathan Burgin brings to his role as CFO in Tarsier Pharma over 20 years of managerial experience and leadership in public biotech and hi-tech companies.

Most recently he served in the position of CFO & COO at Anchiano Therapeutics, a clinical stage biopharmaceutical company developing drugs against cancer (Nasdaq: ANCN, TASE: ANCN), where he played an instrumental role in building the organization and advancing the lead compound to pivotal clinical trials. He also played an integral role in the Nasdaq IPO and multiple private and public offerings while traded on the TASE raising a total of $96M.

Prior to Anchiano, Jonathan was CFO of Radcom Ltd. (Nasdaq: RDCM), a service assurance provider where he led the global finance and related operations. Prior to that, he was CFO of XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, LSE: XTL, TASE: XTL), a drug development company, where he played a leading role in four capital transactions raising over $110M. Prior to that, Jonathan was CFO of YLR Capital Markets Ltd., a publicly-traded Israeli investment bank. Earlier in his career, he served as a Senior Manager at PwC Tel Aviv.

Jonathan holds an MBA in finance and a BA in accounting and economics from Tel Aviv University and is a Certified Public Accountant in Israel. He currently serves on the Board of Directors of Cellect Biotechnology Ltd. (Nasdaq: APOP).

Galit Levin, Ph.D – Head of CMC and Formulation

Dr. Levin has 25 years of experience developing new chemical entities for US and EU markets, from proof of concept and pre-clinical and clinical stages, through technical transfer, scale-up, and until reaching a commercial phase. She has CMC (Chemistry, Manufacturing and Controls) expertise that includes formulation development (liposomes, sterile injection, semi-solid dosage forms, etc), technical transfer, scale-up and validation in start-up and multinational companies as well as a wide experience in regulatory submissions (IND, NDA, IMPD) for US and EU markets.
Dr. Levin’s experience includes project management, budget preparation, contract manufacturer selection and management, and project risk assessment. She has served as Director of CMC and CMC Lead in Neuroderm, a pharmaceutical company developing treatments for central nervous system (CNS) disorders, and as CMC Project Manager in Dexcel Pharma, which develops, manufactures and markets pharmaceutical products. Dr. Levin has a B.Sc in Chemistry, M.Sc and Ph.D in Biochemistry, and an MBA, all from Tel-Aviv University.

Dr. Eidelman has over 40 years of experience in the field of organic synthesis and peptide chemistry, including chemical and analytical R&D, QC, process development and project management. He has over 25 years of experience in development and production of synthetic peptide APIs (Active Pharmaceutical Ingredients). Dr. Eidelman has served as Chief Chemist and VP R&D in Novetide, today a global company developing peptide synthesis technologies and production processes for the APIs’ pharmaceutical industry. He has been instrumental in the company’s evolvement and growth, from its inception as a new spin-off until its success in large global scales, by building the R&D capabilities to serve manufacturing facilities for peptide products, managing various processes such as tech transfer to manufacturing sites, and scaling-up the activity and team. Beforehand Dr. Eidelman has been in ICL (Israel Chemicals Group), first as a Researcher and Project Manager at Monomers and Fine Chemicals Groups, and then as a Project Manager at the Peptide Group. Between 2015-2020 he has also served as a member of United States Pharmacopeia BIO1 Expert Committee, an international expert committee that designs policy and sets standards of peptide products for the US market. Dr. Eidelman has a B.Sc and M.Sc in Chemistry from the Technion Israel Institute of Technology, and a Ph.D in Chemistry from Tel-Aviv university.

Ruti Friedel, MA – Business Development & Community

Ms. Friedel brings experience in developing international partnerships for technology and innovation, inter alia as Director of SMEs Department in ISERD (Israeli-European R&D Directorate) and as Global Business Development and International Collaboration Strategist of Israel Innovation Authority. Participated in designing governmental incentives and in management of foreign relations to support Israeli companies’ R&D cooperation with foreign entities. Also served as a Trade Officer at the Industry and Trade Department in the Mission of Israel to the EU in Brussels, Belgium, where she helped promote Israeli commercial activity in the EU. Ms. Friedel has a BA in French and English Language and Literature from Tel-Aviv University, an MA in European Studies from the Hebrew University of Jerusalem, and an MA in Law from Bar-Ilan University.

Atul Raut, MD, PhD

Dr. Raut is Vice President, Global Business Development at Sun Pharmaceuticals Ltd., the largest pharma company in India where he oversees global business development activities for novel specialty branded products. The activities include in-licensing, out-licensing, Mergers and Acquisition, Joint Ventures, research collaborations with academia and pharma/biotech companies, equity investments as well as investments in venture capitals.

Dr. Raut joined Sun Pharma in 2010 and was responsible for clinical research and development for multiple therapy areas including ophthalmology, dermatology and respiratory.

While working in clinical research, he was also involved in multiple business development activities for branded business and is now responsible for global business development of branded products.

He was involved in the global in-licensing for several innovative products such as Ilumya/Ilumetri, Cequa, Yonsa, Odomzo and multiple other pipeline products.

Before joining Sun, Dr. Raut was working at Alcon Laboratories in the US. Dr. Raut holds MD degree from India and PhD degree from USA.

Susan K. Benton, MBA

Mrs. Benton has over 30 years of experience in the biomedical industry, as an executive and entrepreneur. For the past four years, she has served as the Head of New Products and Business Development at Shire, where she played an instrumental role in the expansion of the Ophthalmology Franchise pipeline. Before joining Shire, Mrs. Benton worked in Global Business Development at Bausch and Lomb Pharmaceuticals prior to the acquisition of the company by Valeant. Her deal sheet includes over 20 transactions to date. She also co-founded and served as the Chief Commercial Officer for Sirion Therapeutics, a biopharmaceutical company that developed and launched Durezol® and Zirgan® in the US market before being acquired by Alcon and Bausch and Lomb respectively. She has served as a strategic consultant for more than a dozen ophthalmic start-up companies in the areas of clinical development, strategic marketing, and commercial and business operations. Before joining the ophthalmic community, Mrs. Benton worked as Head of Consumer and Professional Sales for J&J Lifescan and in Marketing & Sales for Sanofi Pasteur. Mrs. Benton holds an MBA from the Executive Program at the University of South Florida and a B.S. in Biology from Muhlenberg College.

Sascha Bucher

Mr. Bucher is Co-Founder and Partner at Forty51 ventures, a Biotech VC fund in Europe focused on venture formation. Previously, he was Partner and Managing Director Investments at Roivant and Head of Europe. Before that he worked for Roche in numerous Business and Corporate Development functions including as Deputy Head of Global M&A. He was involved in 100+ transactions and negotiated and closed over 50 international deals with an accumulated total deal value of more than 10 billion USD. Prior to Roche, Sascha was a banker at UBS. He holds an MBA in Finance and Economics from the University of Basel and is both a Harvard Business School GMP alumnus and a Certified European Financial Analyst and Asset Manager (CEFA).

Tarsier Pharma - Privacy Policy

We at Tarsier Pharma Ltd. (“Tarsier Pharma”, “we”, “us” or “our”) respect your privacy. This Privacy Policy (“Policy”) explains the accepted privacy practices for our online services at our website (“https://tarsierpharma.com/”). It also describes the rights and options available to you with respect to your personal information.

The Website provides content and information about Tarsier Pharma and its research and development of a novel platform for treatment of ocular inflammatory diseases.

You do not have a legal duty to provide the information and providing it is subject to your unconditional consent. Proving the service of online inquiries on our Website will not be available to those choosing not to provide the information requested.

PERSONAL DATA WE COLLECT

We collect two types of information: information you actively provide us when contacting us or statistical information about use of the Website.

Inquiries. If you wish to send us a query of any kind via our online contact form, you will be required to provide us with your name and email address (“Inquiry Information”). In order to respond to certain queries, we may ask you to provide additional information (such as your telephone number).

Statistical information. When you visit our Website, we may record and collect certain information in relation to your visit and use of the Website, including: IP address (and location), time and date of access, type of browser used, links clicked and the web pages you accessed (“Analytical Information”).

Cookies. We collect Analytical Information through “Cookies”, which are text files, comprised of small amount of data, that are saved on your computer or other device (e.g. smartphone, tablet, etc.) when you use internet and visit various websites. We use cookies for several purposes:

Necessary. Cookies that are strictly necessary for the functioning of the Website. The Website cannot operate properly without these cookies. You can set your browser to block or alert you about these cookies, but some parts of the Website may not function properly.
Statistics. Cookies that help us understand how you and other users interact with our Website by collecting data that does not directly identify you.

The overall personal data outlined above will be referred to as the “Information”.

HOW WE USE YOUR INFORMATION

We use your Information in order to contact you about Inquiries you made and/or to operate the Website.

We may use your Information outlined above for the following purposes:

Operating the Website and providing its features and functionalities;
Contact you about inquiries you made;
Send you email communications concerning our products, programs, developments and other related information. We will send you email communication subject to your explicit consent;

You may ‘opt-out’ of using your data for promotional communications at any time by following the “unsubscribe” link located at the bottom of each message. By doing so, Tarsier Pharma will only delete the Information which is required to contact you for promotional communications, while the rest of the Information you submitted to us which is necessary in order to provide you with the Website’s services will continue to be processed.

Improve and enhance the services and content offered on the Website.

WHEN AND HOW WE SHARE YOUR INFORMATION

We share your Information mainly with our contractors and service providers, strictly for the purpose of helping us with the internal operation of the Website.

We will not share your Information with third parties, except in the events listed below or when you provide your explicit and informed consent:

We will share your Information with our service providers (such as our hosting providers) who assist us with the internal operations of our Website and our services.

These companies are authorized to use your Information only as necessary to provide these services to us and not for their own promotional purposes. We do not sell your Information to third parties

If you have breached any agreement you have with us (including this Policy), abused your rights to use the Websites, or violated any applicable law, your Information may be shared with the competent authorities, law enforcement and third parties (such as legal counsels and advisors), for the purpose of handling of the violation or breach;
If we are required to disclose your Information by a judicial, governmental or regulatory authority;
We will share your Information with members of our family group of companies, who help us process the data for the purpose set out above;
If the operation of the Websites is organized within a different framework, or through another legal structure or entity (e.g. due to a merger or acquisition), we will share your Information to enable the structural change.

FOR HOW LONG WE KEEP YOUR INFORMATION

We will store your data for as long as we deem necessary for the purposes detailed in this Policy

We retain personal data for as long as necessary to fulfil the purposes we collected it for (as detailed above), including for the purposes of satisfying any legal, accounting, or reporting requirements. We, at Tarsier Pharma, always consider the type of information collected, the amount of information, how sensitive it might be. Accordingly, we determine the appropriate retention period.

We may also anonymize your Information so that it can no longer be associated with you, in which case we will use such Information without further notice to you.

HOW DO WE PROTECT YOUR INFORMATION?

We implement measures to reduce the risks of damage and unauthorized access or use of information, including when data is transferred outside the E.U.

Security Measures. We implement measures to reduce the risks of damage, loss of Information and unauthorized access or use of Information. We also request our affiliates to implement such measures in order to secure the Information we provide them. However, although efforts are made to secure your Information, we cannot guarantee its absolute protection.

Cross-Border Data Transfers. We are based in Israel. Information we collect from you will be processed in Israel, which is recognized by the European Commission as having adequate protection for personal data. Certain information may be stored externally via cloud services. We will only transfer your personal information to a country or company which has been deemed to have an adequate level of data protection by the EU commission, or under other adequate safeguards determined under the applicable law.

ADDITIONAL INFORMATION FOR E.U RESIDENTS

Controller. Tarsier Pharma Ltd. is the data controller for the purposes of the personal data we collect via the Website and for the performance of the services offered through the Website.

LEGAL BASIS FOR PROCESSING YOUR DATA

The legal basis for processing and collecting Inquiry Information is its necessity for the provision of feedback, comment or service in response to your inquiry;
The legal basis for processing and collecting Analytical Information is our legitimate interests in operating our website, ongoing management of our business and business development;
The legal basis for collecting and processing your information for Promotional Communications is your explicit consent;

YOUR RIGHTS. You have the following rights under the GDPR:

Right to Access. You have a right to access your personal data that we process and receive a copy of it.
Right to Rectification. You have the right to ask us to rectify inaccurate personal data concerning you and to have incomplete personal data completed.
Right to Data Portability. You have a right to receive the personal data that you provided to us, in a structured, commonly used and machine-readable format. You have the right to transmit this data to a third party. Where technically feasible, you have the right that your personal data be transmitted directly from us to a third party you designated.
Right to Withdraw Consent. You have the right to withdraw your consent for processing your personal data at any time. If you do that, we will not collect any further personal data, but we will further process the data we already collected for reasons described in this Policy. Withdrawing your consent will not affect the lawfulness of data processing we carried out based on your consent before such withdrawal.
Right to Object. If you previously agreed that your personal data may be used for other purposes other than registering and/or placing an order, you may have a right to object to the use of your personal data for such additional purposes.
Right to Restrict. You have the right to restrict processing of your personal data (except for storing it) if you contest the accuracy of your personal data, for a period enabling us to verify its accuracy; if you believe that the processing is unlawful and you opposes the erasure of the personal data and requests instead to restrict its use; if we no longer need the personal data for the purposes outlined in this Policy, but they are required by you to establish, exercise or defence relating to legal claims, or if you object to processing, pending the verification whether our legitimate grounds for processing override yours.
Right to be Forgotten. Under certain circumstances, such as when you withdraw your consent, you have the right to ask us to erase your personal data. However, we may still process your personal data if it is necessary to comply with a legal obligation we are subject to under laws in EU Member States.

If you believe your right have been infringed, you can lodge a complaint with a supervisory authority operating under the GDPR. For a list of supervisory authorities in the EU, click here.

Representation for data subjects in the EU
We value your privacy and your rights as a data subject and have therefore appointed Prighter Group with its local partners as our privacy representative and your point of contact.
Prighter gives you an easy way to exercise your privacy-related rights (e.g. requests to access or erase personal data). If you want to contact us via our representative Prighter or make use of your data subject rights, please visit the following website. https://prighter.com/q/11999524960

POLICY AMENDMENTS

From time to time, we may change this Policy. We will provide you notice of such changes through the Website interface.

CONTACT US

You may contact us through our Website by completing our online form or via email at [email protected], We will do our best to resolve your issue promptly.

Last update: April, 2022

Tarsier Pharma - Privacy Policy

We at Tarsier Pharma Ltd. (“Tarsier Pharma”, “we”, “us” or “our”) respect your privacy. This Privacy Policy (“Policy”) explains the accepted privacy practices for our online services at our website (“https://tarsierpharma.com/”). It also describes the rights and options available to you with respect to your personal information.

The Website provides content and information about Tarsier Pharma and its research and development of a novel platform for treatment of ocular inflammatory diseases.

You do not have a legal duty to provide the information and providing it is subject to your unconditional consent. Proving the service of online inquiries on our Website will not be available to those choosing not to provide the information requested.

PERSONAL DATA WE COLLECT

We collect two types of information: information you actively provide us when contacting us or statistical information about use of the Website.

Inquiries. If you wish to send us a query of any kind via our online contact form, you will be required to provide us with your name and email address (“Inquiry Information”). In order to respond to certain queries, we may ask you to provide additional information (such as your telephone number).

Statistical information. When you visit our Website, we may record and collect certain information in relation to your visit and use of the Website, including: IP address (and location), time and date of access, type of browser used, links clicked and the web pages you accessed (“Analytical Information”).

Cookies. We collect Analytical Information through “Cookies”, which are text files, comprised of small amount of data, that are saved on your computer or other device (e.g. smartphone, tablet, etc.) when you use internet and visit various websites. We use cookies for several purposes:

Necessary. Cookies that are strictly necessary for the functioning of the Website. The Website cannot operate properly without these cookies. You can set your browser to block or alert you about these cookies, but some parts of the Website may not function properly.
Statistics. Cookies that help us understand how you and other users interact with our Website by collecting data that does not directly identify you.

The overall personal data outlined above will be referred to as the “Information”.

HOW WE USE YOUR INFORMATION

We use your Information in order to contact you about Inquiries you made and/or to operate the Website.

We may use your Information outlined above for the following purposes:

Operating the Website and providing its features and functionalities;
Contact you about inquiries you made;
Send you email communications concerning our products, programs, developments and other related information. We will send you email communication subject to your explicit consent;

You may ‘opt-out’ of using your data for promotional communications at any time by following the “unsubscribe” link located at the bottom of each message. By doing so, Tarsier Pharma will only delete the Information which is required to contact you for promotional communications, while the rest of the Information you submitted to us which is necessary in order to provide you with the Website’s services will continue to be processed.

Improve and enhance the services and content offered on the Website.

WHEN AND HOW WE SHARE YOUR INFORMATION

We share your Information mainly with our contractors and service providers, strictly for the purpose of helping us with the internal operation of the Website.

We will not share your Information with third parties, except in the events listed below or when you provide your explicit and informed consent:

We will share your Information with our service providers (such as our hosting providers) who assist us with the internal operations of our Website and our services.

These companies are authorized to use your Information only as necessary to provide these services to us and not for their own promotional purposes. We do not sell your Information to third parties

If you have breached any agreement you have with us (including this Policy), abused your rights to use the Websites, or violated any applicable law, your Information may be shared with the competent authorities, law enforcement and third parties (such as legal counsels and advisors), for the purpose of handling of the violation or breach;
If we are required to disclose your Information by a judicial, governmental or regulatory authority;
We will share your Information with members of our family group of companies, who help us process the data for the purpose set out above;
If the operation of the Websites is organized within a different framework, or through another legal structure or entity (e.g. due to a merger or acquisition), we will share your Information to enable the structural change.

FOR HOW LONG WE KEEP YOUR INFORMATION

We will store your data for as long as we deem necessary for the purposes detailed in this Policy

We retain personal data for as long as necessary to fulfil the purposes we collected it for (as detailed above), including for the purposes of satisfying any legal, accounting, or reporting requirements. We, at Tarsier Pharma, always consider the type of information collected, the amount of information, how sensitive it might be. Accordingly, we determine the appropriate retention period.

We may also anonymize your Information so that it can no longer be associated with you, in which case we will use such Information without further notice to you.

HOW DO WE PROTECT YOUR INFORMATION?

We implement measures to reduce the risks of damage and unauthorized access or use of information, including when data is transferred outside the E.U.

Security Measures. We implement measures to reduce the risks of damage, loss of Information and unauthorized access or use of Information. We also request our affiliates to implement such measures in order to secure the Information we provide them. However, although efforts are made to secure your Information, we cannot guarantee its absolute protection.

Cross-Border Data Transfers. We are based in Israel. Information we collect from you will be processed in Israel, which is recognized by the European Commission as having adequate protection for personal data. Certain information may be stored externally via cloud services. We will only transfer your personal information to a country or company which has been deemed to have an adequate level of data protection by the EU commission, or under other adequate safeguards determined under the applicable law.

ADDITIONAL INFORMATION FOR E.U RESIDENTS

Controller. Tarsier Pharma Ltd. is the data controller for the purposes of the personal data we collect via the Website and for the performance of the services offered through the Website.

LEGAL BASIS FOR PROCESSING YOUR DATA

The legal basis for processing and collecting Inquiry Information is its necessity for the provision of feedback, comment or service in response to your inquiry;
The legal basis for processing and collecting Analytical Information is our legitimate interests in operating our website, ongoing management of our business and business development;
The legal basis for collecting and processing your information for Promotional Communications is your explicit consent;

YOUR RIGHTS. You have the following rights under the GDPR:

Right to Access. You have a right to access your personal data that we process and receive a copy of it.
Right to Rectification. You have the right to ask us to rectify inaccurate personal data concerning you and to have incomplete personal data completed.
Right to Data Portability. You have a right to receive the personal data that you provided to us, in a structured, commonly used and machine-readable format. You have the right to transmit this data to a third party. Where technically feasible, you have the right that your personal data be transmitted directly from us to a third party you designated.
Right to Withdraw Consent. You have the right to withdraw your consent for processing your personal data at any time. If you do that, we will not collect any further personal data, but we will further process the data we already collected for reasons described in this Policy. Withdrawing your consent will not affect the lawfulness of data processing we carried out based on your consent before such withdrawal.
Right to Object. If you previously agreed that your personal data may be used for other purposes other than registering and/or placing an order, you may have a right to object to the use of your personal data for such additional purposes.
Right to Restrict. You have the right to restrict processing of your personal data (except for storing it) if you contest the accuracy of your personal data, for a period enabling us to verify its accuracy; if you believe that the processing is unlawful and you opposes the erasure of the personal data and requests instead to restrict its use; if we no longer need the personal data for the purposes outlined in this Policy, but they are required by you to establish, exercise or defence relating to legal claims, or if you object to processing, pending the verification whether our legitimate grounds for processing override yours.
Right to be Forgotten. Under certain circumstances, such as when you withdraw your consent, you have the right to ask us to erase your personal data. However, we may still process your personal data if it is necessary to comply with a legal obligation we are subject to under laws in EU Member States.

If you believe your right have been infringed, you can lodge a complaint with a supervisory authority operating under the GDPR. For a list of supervisory authorities in the EU, click here.

Representation for data subjects in the EU
We value your privacy and your rights as a data subject and have therefore appointed Prighter Group with its local partners as our privacy representative and your point of contact.
Prighter gives you an easy way to exercise your privacy-related rights (e.g. requests to access or erase personal data). If you want to contact us via our representative Prighter or make use of your data subject rights, please visit the following website. https://prighter.com/q/11999524960

POLICY AMENDMENTS

From time to time, we may change this Policy. We will provide you notice of such changes through the Website interface.

CONTACT US

You may contact us through our Website by completing our online form or via email at [email protected], We will do our best to resolve your issue promptly.

Last update: April, 2022

Prof. Emmett Cunningham, Jr, MD, Ph.D, MPH

Dr. Cunningham serves as Managing director at Clarus ventures. He joined Clarus in 2006 with extensive experience in the biomedical and biopharmaceutical sectors. Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc (NYSE: PFE), where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology.
Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications. He is Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute. He completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in London, and a fellowship in public health ophthalmology at the Wilmer Eye Institute in Baltimore.

Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit, a symposium held in conjunction with the annual meetings of the American Academy of Ophthalmology, the American Society of Cataract and Refractive Surgery and the American Society of Retinal Surgeons.

Dr. Cunningham represents Clarus on the Board of Directors of Annexon Biosciences, Graybug Vision, Restoration Robotics, and SFJ Pharmaceuticals Group. He is a Board observer for Lumos Pharma and is on the Scientific Advisory Board of Aerie Pharmaceuticals (NASDAQ: AERI).

Previous Directorships include Neomend (acquired by Bard) and SARcode Biosciences (acquired by Shire). Additionally, he was Board Observer for Avillion, Ferrokin (acquired by Shire), Ophthotech (NASDAQ: OPHT), Pearl Therapeutics (acquired by AstraZeneca), and was a member of the Scientific Advisory Board for ESBATech (acquired by Alcon).

Prof. Marc de Smet, MDCM, Ph.D, FRCSC, FRCOphth, DABO, FMH

Prof. de Smet is an internationally recognized expert in medical and surgical retina, including management of complex ocular inflammatory conditions. He currently serves as the Executive Director of the MicroInvasive Ocular Surgery Clinic (MIOS) in Lausanne, Switzerland. Prof. de Smet previously served as the Former Chair, Department of Ophthalmology at the University of Amsterdam, is an Honorary Professor, University of Leiden, and Adjunct Professor, New York Eye and Ear Infirmary of Mt Sinai, Icahn School of Medicine. Prof. de Smet is the former Chief Medical Officer of Oxular Ltd and Preceyes B.V. and also worked at the National Institutes of Health Eye Institute in the field of ocular inflammation, where he led a translational research team focused on better understanding and treating eye inflammation. His research interests include retinal imaging, pharmacology as applied to retinal diseases, the use of methotrexate in eyes for the treatment of ocular lymphoma, the use of steroids for various ocular indications, and development of robotic surgical platforms for eye surgery. Prof. de Smet has published more than 200 articles, 25 books and book chapters, and given numerous lectures and named lectures. He is a member of the executive board for the International Uveitis Study Group (IUSG) and currently serves as secretary of the IUSG. Prof. de Smet trained in medicine at McGill University in Canada, in ophthalmology and ophthalmic surgery at the University of British Columbia, and completed a fellowship in surgical retina at Johns Hopkins, Wilmer Eye Institute.

Prof. Quan Dong Nguyen,MD, MSc

Dr. Quan Dong Nguyen currently is a Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine.

Dr. Nguyen received his Bachelor and Master of Science degrees simultaneously in Molecular Biophysics and Biochemistry from Yale University, and earned his medical degree at the University of Pennsylvania School of Medicine. He completed an internship in Internal Medicine at the Massachusetts General Hospital and a residency in Ophthalmology at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Dr. Nguyen also completed fellowships in Immunology and Uveitis at the Massachusetts Eye and Ear Infirmary, Ocular Immunology at the Wilmer Eye Institute of the Johns Hopkins Medical Institutions, and medical and surgical retina at the Schepens Eye Research Institute and the Massachusetts Eye and Ear Infirmary.

In 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, and Assistant Dean for Translational Research at the University of Nebraska Medical Center.

Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other organizations for macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases, as well as co-investigator on numerous other clinical trials involving novel therapeutic agents. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. Dr. Nguyen and his team were among the first clinician scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME); the initial results of these studies served as the foundation for subsequent trials leading to the approval of these pharmacologic agents by the FDA and other regulatory authorities for the indicated diseases. Dr. Nguyen has chaired the United States multi-center READ-2, READ-3, and iDEAL studies, evaluating the potential role of VEGF antagonists, through different pathways, for diabetic macular edema.

Dr. Nguyen has lead the SAVE, and the multi-centered SAVE-2, and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition, in uveitis and ocular inflammatory diseases.

At the Byers Eye Institute at Stanford, Dr. Nguyen has an active uveitis and ocular inflammatory diseases as well as clinical and surgical retina practice while he continues his research in pharmacotherapy and ocular imaging. In addition, he teaches and trains students, residents, and clinical and research retina and uveitis fellows at Stanford.

Ron Neumann, MD - CMO

Dr. Neumann is an ophthalmologist, specializing in ocular immunology & clinical uveitis. He specialized in Inflammatory Eye Diseases (IED) at Mass Eye and Ear Infirmary, Harvard University and was formerly the Head of IED at Sheba Hospital. Together with his clinical expertise, he brings vast experience from the pharmaceutical industry as former Head of global medical affairs and ophthalmology clinical development at Teva Pharmaceutical Ltd. He was involved in the early stage of a small company (Pharmos) as their head of ophthalmic development, and was later leading contract research within an HMO (Maccabi healthcare organization). Since 1995, he is the Founder and co-chairman of the international Symposium of Ocular Pharmacology and Therapeutics, ISOPT Clinical.

Zohar Milman, M.Sc - COO

Ms. Milman brings hands-on experience from drug development projects, among them Orphan Technologies, a company focused on development of novel drugs for rare, life-threatening diseases that was acquired by Retrophin (NASDAQ: RTRX) in a deal worth $517M. On top of that, Ms. Milman brings diverse experience from a venture capital firm, where she managed due diligence processes for hundreds of early-stage projects, and establishment of early-stage medical device and pharmaceutical start-up companies.

Ms. Milman has been instrumental in Tarsier Pharma’s speedy and successful evolvement, as she heavily contributed to bringing Tarsier from pre-clinical PoC to a phase-3 late-stage pharmaceutical company, in only 5 years. As COO of the company since its inception, Ms. Milman managed numerous aspects of corporate activity, from R&D, pre-clinical, CMC, through regulation and patents, while supporting clinical, legal, business development, marketing and fund raising activities.

Ms. Milman holds an M.Sc. in Biomedical Sciences and Human Genetics from the Hebrew University of Jerusalem, Israel.

Olivier Defert, PhD - VP R&D

Dr. Defert has over 15 years of experience in the industry. In his most recent position, Dr. Defert co-founded Amakem NV and Ophthakem NV, where he also served for 8 years as Head of R&D and member of the executive management team. In these positions, he led IND-enabling studies contract research management, medicinal chemistry and projects management of a novel locally acting Rho kinase inhibitor for the treatment of glaucoma – with Clinical Phases 2 completed or ongoing in different countries. Olivier holds a Ph.D. in medicinal chemistry, DeVGen NV and the Laboratoire de Chimie des Biomolécules (Lille). He is the author of 19 patent applications and 10 peer-reviewed publications.

Daphne Haim-Langford, PhD - Founder & CEO

Dr. Haim-Langford is the founder and CEO of Tarsier Pharma, bringing over 20 years of experience in the biomedical industry as an investor, entrepreneur, and executive. Before establishing Tarsier Pharma, she served as Vice President of Business Development at Xenia Venture Capital, where she oversaw the life sciences practice, led investments in medical technology and biotechnology, and served on the boards of various pharmaceutical, medical device, and biotech companies at different stages of development, from early pre-clinical to clinical trials, sales and marketing, and mergers and acquisitions. Notable examples of her involvement include Meditate (acquired by Olympus for up to $285 million) and Orthospace (acquired by Stryker for up to $220 million), among others. At Xenia, she also co-founded and chaired the board of Eximore, an ophthalmic drug delivery company.

Prior to her role at Xenia, Dr. Haim-Langford was VP of Business Development at Medingo, which was acquired by Roche for $200 million. She co-founded and served as the chairperson of the Israeli Biomimicry Organization, a nonprofit aimed at raising awareness of biomimicry and promoting nature-inspired biomedical innovations. In recognition of her lifelong commitment to innovation, she received the prestigious €100,000 European Women Innovation Award in 2021.

Dr. Haim-Langford holds a Ph.D. in Biophysics from the Technion, the Israeli Institute of Technology.

OUR COMPANY

LEADERSHIP TEAM

Emilee Fulcher

Ron Neumann

Daphne Haim-Langford

Zohar Milman

Ashley Hartmann Kline

Arie Ganot

Natan Haykin

In memory of Chaim Eidelman 1955-2022

Daphne Haim-Langford

Zohar Milman

Ron Neumann

Emilee Fulcher

Ashley Hartmann Kline

Arie Ganot

Natan Haykin

In memory of Chaim Eidelman 1955-2022

BOARD OF DIRECTORS

Atul Raut

Susan K. Benton

Daphne Haim-Langford

Sascha Bucher

SCIENTIFIC ADVISORY BOARD

Prof. Marc de Smet

Prof. Meghan Berkenstock

Prof. Quan Dong Nguyen

Prof. Jennifer Thorne

Prof. Mina B. Pantcheva

Prof. Alan Palestine